Sonidegib (Odomzo): A second Hedgehog pathway inhibitor approved as new treatment for most common form of advanced skin cancer

Last Updated on

August 02, 2015 – The American Food and Drug Administration (FDA) very recently approved Sonidegib (Odomzo) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.

Sonidegib (Odomzo) works by inhibiting a molecular pathway, called the Hedgehog pathway, which is active in basal cell cancers. By suppressing this pathway, Sonidegib (Odomzo) may stop or reduce the growth of cancerous lesions. In 2012, Vismodegib (Erivedge) was the first drug approved to

Basal Cell Carcinoma

Basal Cell Carcinoma

treat locally advanced and metastatic basal cell carcinoma. Thanks to an ever increasing understanding of the Hedgehog pathway and its involvement in the etiology of basal cell carcinoma, the FDA has been able to approve two drugs for the treatment of basal cell carcinoma just in the last three years.

The efficacy of Sonidegib (Odomzo) was established in a multi-center, double-blind clinical trial, in which 66 patients with locally advanced basal cell carcinoma were randomly assigned to receive Sonidegib (Odomzo) 200 mg daily and 128 patients were assigned to receive Sonidegib (Odomzo) 800 mg daily. The study’s primary endpoint was objective response rate, which is the percentage of patients who experienced partial shrinkage or complete disappearance of their tumor(s). Results showed that 58 percent of patients treated with Sonidegib (Odomzo) 200 mg had their tumors shrink or disappear. This effect lasted at least 1.9 to 18.6 months, and approximately half of the responding patients’ tumor shrinkage lasted six months or longer. Response rates were similar in patients who received Sonidegib (Odomzo) 800 mg daily, however side effects were more common at this dose.

Sonidegib (Odomzo) comes with a selection of serious adverse effects. Thus, at a dose of 200 mg daily, the most common side effects of Sonidegib (Odomzo) were muscle spasms, alopecia (hair loss), dysgeusia (distortion in the sense of taste), fatigue, nausea, musculoskeletal pain, diarrhea, decreased weight, decreased appetite, myalgia (muscle pain), abdominal pain, headache, pain, vomiting and pruritus (itching). Sonidegib (Odomzo) also has the potential to cause serious musculoskeletal-related side effects, including increased serum creatine kinase levels [with rare reports of muscle tissue breakdown (rhabdomyolysis)], muscle spasms, and myalgia.

Sonidegib (Odomzo) also carries a Boxed Warning alerting healthcare professionals that Sonidegib (Odomzo) may cause death or severe birth defects in a developing fetus when administered to a pregnant woman. Pregnancy status should be verified prior to the start of Sonidegib (Odomzo) treatment, and both male and female patients should be warned about these risks and advised to use effective contraception.

Skin cancer is an important indication. It is the most common cancer and basal cell carcinoma accounts for approximately 80 percent of non-melanoma skin cancers. Basal cell carcinoma starts in the top layer of the skin (called the epidermis) and usually develops in areas that have been regularly exposed to the sun and other forms of ultraviolet radiation. According to the National Cancer Institute, the number of new cases of non-melanoma skin cancer appears to be increasing every year. Locally advanced basal cell skin cancer refers to basal cancers that have not spread to other parts of the body, but cannot be curatively treated with local treatments, specifically surgery and radiation.

Tags: , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login

Notify of
Rochell Dittus

some genuinely excellent posts on this web site, thanks for contribution.


Inspiring quest there. What occurred after?
Good luck!

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Scientists use gene-editing tool CRISPR in attempt to cure HIV September 13, 2019
    The first attempt to use the gene-editing tool CRISPR to cure HIV infection was unsuccessful but the approach does show promise.
  • New cardiac fibrosis study identifies key proteins that translate into heart disease September 12, 2019
    Using cutting-edge technologies, researchers at Duke-NUS Medical School, Singapore, have developed the first genome-wide dataset on protein translation during fibroblast activation, revealing a network of RNA-binding proteins (RBPs) that play a key role in the formation of disease-causing fibrous tissue in the heart. Their findings, published in the journal Circulation, could help in the search […]
  • How your genes affect the number on your scale September 12, 2019
    Could your genes be keeping you from losing weight?
  • Scientists identify gene as master regulator in schizophrenia September 11, 2019
    Using computational tools to investigate gene transcription networks in large collections of brain tissues, a scientific team has identified a gene that acts as a master regulator of schizophrenia during early human brain development. The findings may lay the groundwork for future treatments for the highly complex neuropsychiatric disorder.
  • How your DNA takes shape makes a big difference in your health September 11, 2019
    The more we learn about our genome, the more mysteries arise. For example, how can people with the same disease-causing mutation have different disease progression and symptoms? And despite the fact that it's been more than 15 years since the human genome was sequenced, why can't we explain the significance of the vast majority of […]